This Medicine requires a physician's prescription.

Generic Name: Sitagliptin Phosphate Metformin HCI

Brand Name: Janumet™ XR

Strength: 100mg / 1g

Form: Extended Release Film-Coated Tablet

Manufacturer: MSD International GmbH (Puerto Rico Branch) LLC

Packed by: Merck Sharp and Dohme B.V

Classification: Antidiabetic Agents

Indication/Uses: SITAGLIPTIN PHOSPHATE + METFORMIN HCl (JANUMET XR) is indicated as initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control.

SITAGLIPTIN PHOSPHATE + METFORMIN HCl (JANUMET XR) is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin.

SITAGLIPTIN PHOSPHATE + METFORMIN HCl (JANUMET XR) is indicated as part of triple combination therapy with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: Metformin, sitagliptin, or a sulfonylurea.

SITAGLIPTIN PHOSPHATE + METFORMIN HCl (JANUMET XR) is indicated as part of triple combination therapy with a PPARγ agonist (i.e., thiazolidinediones) as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: Metformin, sitagliptin, or a PPARγ agonist.

SITAGLIPTIN PHOSPHATE + METFORMIN HCl (JANUMET XR) is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in combination with insulin.